{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:38:59Z","timestamp":1776731939466,"version":"3.51.2"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T00:00:00Z","timestamp":1452124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T00:00:00Z","timestamp":1452124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/jhh.2015.125","type":"journal-article","created":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T10:20:59Z","timestamp":1452162059000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combination therapy of renin\u2013angiotensin system inhibitors plus calcium channel blockers versus other two-drug combinations for hypertension: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"31","author":[{"given":"Z","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,7]]},"reference":[{"issue":"1","key":"BFjhh2015125_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/08037051.2014.868629","volume":"23","author":"G Mancia","year":"2014","unstructured":"Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH\/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2014; 23 (1): 3\u201316.","journal-title":"Blood Press"},{"issue":"8","key":"BFjhh2015125_CR2","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1097\/HJH.0b013e328348345d","volume":"29","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29 (8): 1649\u20131659.","journal-title":"J Hypertens"},{"key":"BFjhh2015125_CR3","unstructured":"WHO World Health Statistics. WHO: Geneva, Switzerland, 2012."},{"issue":"9395","key":"BFjhh2015125_CR4","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","volume":"362","author":"F Turnbull","year":"2003","unstructured":"Turnbull F . Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362 (9395): 1527\u20131535.","journal-title":"Lancet"},{"issue":"5","key":"BFjhh2015125_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1291\/hypres.28.385","volume":"28","author":"JA Staessen","year":"2005","unstructured":"Staessen JA, Li Y, Thijs L, Wang JG . Blood pressure reduction and cardiovascular prevention: an update including the 2003\u20132004 secondary prevention trials. Hypertens Res 2005; 28 (5): 385\u2013407.","journal-title":"Hypertens Res"},{"issue":"7404","key":"BFjhh2015125_CR6","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE . Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326 (7404): 1427.","journal-title":"BMJ"},{"issue":"23","key":"BFjhh2015125_CR7","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981\u20132997.","journal-title":"JAMA"},{"issue":"9489","key":"BFjhh2015125_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahlof","year":"2005","unstructured":"Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895\u2013906.","journal-title":"Lancet"},{"issue":"9118","key":"BFjhh2015125_CR9","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351 (9118): 1755\u20131762.","journal-title":"Lancet"},{"key":"BFjhh2015125_CR10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"358","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (Life): a randomised trial against atenolol. Lancet 2002; 358: 995\u20131003.","journal-title":"Lancet"},{"issue":"5","key":"BFjhh2015125_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311 (5): 507\u2013520.","journal-title":"JAMA"},{"issue":"1","key":"BFjhh2015125_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jch.12237","volume":"16","author":"MA Weber","year":"2014","unstructured":"Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 2014; 16 (1): 14\u201326.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"BFjhh2015125_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0000000000000065","volume":"32","author":"MA Weber","year":"2014","unstructured":"Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32 (1): 3\u201315.","journal-title":"J Hypertens"},{"issue":"9204","key":"BFjhh2015125_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","volume":"355","author":"M Burnier","year":"2000","unstructured":"Burnier M, Brunner HR . Angiotensin II receptor antagonists. Lancet 2000; 355 (9204): 637\u2013645.","journal-title":"Lancet"},{"issue":"6","key":"BFjhh2015125_CR15","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1161\/01.CIR.103.6.904","volume":"103","author":"M Burnier","year":"2001","unstructured":"Burnier M . Angiotensin II type 1 receptor blockers. Circulation 2001; 103 (6): 904\u2013912.","journal-title":"Circulation"},{"issue":"9246","key":"BFjhh2015125_CR16","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(00)03306-7","volume":"356","author":"M Pahor","year":"2000","unstructured":"Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356 (9246): 1949\u20131954.","journal-title":"Lancet"},{"issue":"11","key":"BFjhh2015125_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1524-6175.2004.03683.x","volume":"6","author":"J Basile","year":"2004","unstructured":"Basile J . The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens (Greenwich) 2004; 6 (11): 621\u2013629 630-631.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"BFjhh2015125_CR18","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.","journal-title":"BMJ"},{"key":"BFjhh2015125_CR19","unstructured":"Higgins JASG Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available at (http:\/\/www.cochrane-handbook.org)."},{"key":"BFjhh2015125_CR20","doi-asserted-by":"crossref","unstructured":"Wiysonge CS1, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH . Beta-blockers for hypertension. Cochrane Database Syst Rev 2012; 11: CD002003.","DOI":"10.1002\/14651858.CD002003.pub4"},{"issue":"2","key":"BFjhh2015125_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.amjmed.2010.08.007","volume":"124","author":"H Makani","year":"2011","unstructured":"Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH . Effect of renin\u2013angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011; 124 (2): 128\u2013135.","journal-title":"Am J Med"},{"key":"BFjhh2015125_CR22","first-page":"D1841","volume":"3","author":"JM Wright","year":"2009","unstructured":"Wright JM, Musini VM . First-line drugs for hypertension. Cochrane Database Syst Rev 2009; 3: D1841.","journal-title":"Cochrane Database Syst Rev"},{"key":"BFjhh2015125_CR23","first-page":"CD003654","volume":"8","author":"C Ning","year":"2010","unstructured":"Ning C, Muke Z, Mi Y, Jian G, Cairong Z, Jie Y et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev 2010; 8: CD003654.","journal-title":"Cochrane Database Syst Rev"},{"key":"BFjhh2015125_CR24","first-page":"D8170","volume":"1","author":"H Xue","year":"2015","unstructured":"Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 2015; 1: D8170.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/jhh2015125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh2015125","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh2015125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T20:06:17Z","timestamp":1647547577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh2015125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["BFjhh2015125"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2015.125","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,7]]},"assertion":[{"value":"6 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}